Status: Recruiting
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
This is a multi-center, randomized, double-blinded, placebo controlled trial.
Participants needed: 366
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Priothera SASUpdated: Jun 22, 2026Locations: 110
Eligibility criteria
Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2... [+6]
Use of CsA, anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD proph... [+7]